THE ULTIMATE GUIDE TO HOW TO USE MOUNJARO

The trial obtained both of those its primary endpoints, with semaglutide 2.4 mg demonstrating statistically significant and superior improvements in liver fibrosis without having worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in those with MASH when compared with placebo.1Semaglutide is av